Primary Tumor Heterogeneity on Pre-treatment [68Ga]Ga-PSMA PET/CT for the Prediction of Biochemical Recurrence in Prostate Cancer Heterogeneidad del tumor primario en la PET/TC con [68Ga]Ga-PSMA previa al tratamiento para la predicción de la recurrencia bioquímica en el cáncer de próstata
Revista Espanola de Medicina Nuclear e Imagen Molecular, cilt.43, sa.6, 2024 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 43 Sayı: 6
- Basım Tarihi: 2024
- Doi Numarası: 10.1016/j.remn.2024.500032
- Dergi Adı: Revista Espanola de Medicina Nuclear e Imagen Molecular
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Anahtar Kelimeler: [68Ga]Ga-PSMA PET, Prostate cancer, Radiomics, Texture analysis, Tumor heterogeneity
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: The aim of this study is to research the value of the texture analysis of primary tumors in pre-treatment [68Ga]Ga-PSMA PET in the prediction of the development of biochemical recurrence (BCR) in prostate cancer patients who underwent definitive therapies. Methods: Fifty-one patients with prostate adenocarcinoma who had a pre-treatment [68Ga]Ga-PSMA-11 PET/CT and underwent definitive radiotherapy (RT) or radical prostatectomy (RP) were included in the study. Demographics, clinicopathologic features, the presence of BCR, and the last follow-up date of patients were recorded. Textural and conventional PET parameters (maximum standardized uptake value (SUVmax), total lesion-PSMA (TL-PSMA), and PSMA-tumor volume (PSMA-TV)) were obtained from PET/CT images using LifeX program. Parameters were grouped using the Youden index in ROC analysis. Factors predicting the BCR were determined using Cox regression analyses. Results: Twenty-nine (56.9%) patients have received primary curative RT, while the remaining 22 (43.1%) patients have undergone RP. 5 (22.7%) patients with RP and 3 (10.3%) patients with curative RT have developed BCR during the follow-up. INTENSITY-BASED-minimum grey level (P=.050), GLCM-sum variance (P=.019), and GLCM-cluster prominence (P=.050) were associated with BCR in univariate analysis. INTENSITY-BASED-minimum grey level (P=.009) and GLCM-sum variance (P=.004) were found as independent predictors of BCR in the multivariate analysis. Conclusion: Tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET is associated with a high risk of BCR in PCa patients who underwent definitive therapies.